Roy Baynes Sells 4,500 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Posted by Stanley Muller on Jun 18th, 2026

Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) Director Roy Baynes sold 4,500 shares of the stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $50.00, for a total value of $225,000.00. Following the completion of the sale, the director directly owned 41,500 shares of the company’s stock, valued at approximately $2,075,000. This represents a 9.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Stock Performance

Shares of TVTX stock opened at $54.14 on Thursday. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 3.08. Travere Therapeutics, Inc. has a fifty-two week low of $13.88 and a fifty-two week high of $55.11. The stock’s 50-day moving average is $43.07 and its two-hundred day moving average is $35.63. The firm has a market cap of $5.03 billion, a P/E ratio of -235.38 and a beta of 1.13.

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last issued its earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The company had revenue of $127.20 million for the quarter, compared to analyst estimates of $136.23 million. During the same period in the prior year, the firm posted ($0.47) EPS. The business’s revenue was up 55.6% compared to the same quarter last year. Analysts predict that Travere Therapeutics, Inc. will post -0.29 earnings per share for the current fiscal year.

Institutional Trading of Travere Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System grew its holdings in Travere Therapeutics by 32.3% in the 1st quarter. California State Teachers Retirement System now owns 105,132 shares of the company’s stock valued at $3,123,000 after buying an additional 25,660 shares during the last quarter. Elmind Capital LP lifted its position in shares of Travere Therapeutics by 61.5% in the 1st quarter. Elmind Capital LP now owns 177,600 shares of the company’s stock worth $5,276,000 after acquiring an additional 67,600 shares during the period. Empowered Funds LLC lifted its position in shares of Travere Therapeutics by 2,719.8% in the 1st quarter. Empowered Funds LLC now owns 84,820 shares of the company’s stock worth $2,520,000 after acquiring an additional 81,812 shares during the period. Quantinno Capital Management LP lifted its position in shares of Travere Therapeutics by 354.4% in the 1st quarter. Quantinno Capital Management LP now owns 68,317 shares of the company’s stock worth $2,030,000 after acquiring an additional 53,283 shares during the period. Finally, Rice Hall James & Associates LLC lifted its position in shares of Travere Therapeutics by 1.3% in the 1st quarter. Rice Hall James & Associates LLC now owns 92,757 shares of the company’s stock worth $2,756,000 after acquiring an additional 1,221 shares during the period.

Wall Street Analyst Weigh In

Several brokerages have weighed in on TVTX. Canaccord Genuity Group upped their target price on Travere Therapeutics from $47.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. Weiss Ratings raised Travere Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 21st. Guggenheim increased their price objective on Travere Therapeutics from $54.00 to $56.00 and gave the company a “buy” rating in a report on Friday, April 24th. Citigroup increased their price objective on Travere Therapeutics from $62.00 to $70.00 and gave the company a “buy” rating in a report on Monday. Finally, HC Wainwright increased their price objective on Travere Therapeutics from $57.00 to $67.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Travere Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $50.83.

Read Our Latest Research Report on Travere Therapeutics

About Travere Therapeutics

(Get Free Report)

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.